Skip to main content
. 2014 Mar 20;5(7):1846–1855. doi: 10.18632/oncotarget.1834

Table 4. Stable Disease > 6 months or Partial Response (PR) by RECIST and Characterization by Patient.

Disease Site Histology Dose Level Best Response # of Prior Cytotoxic Regimens Duration of Treatment (weeks) PTEN* PI3K Mutation RAS Mutation RAF Mutation
Uterus Clear Cell Carcinoma 5 -39% 3 36 ND Y ND N
Ovary High Grade Serous 13 -33% 4 27 ND N N N
Cervix Squamous 6 -43% 3 18 ND N ND ND
Ovary High Grade Serous 13 -59% 7 63+ ND N ND N
Uterus Epithelial 13 -38% 4 21 P N N ND
Ovary High Grade Serous 13 -50% 2 48 ND ND ND ND
Cervix Squamous 13 -68% 1 60+ ND ND ND ND
Peritoneum High Grade Serous 2 0% 4 24 ND N ND ND
Ovary High Grade Serous 3 -7% 5 36 ND N ND ND
Uterus Epithelial 8 Non-measurable by RECIST 1 36 ND N N ND
Ovary High Grade Serous 12 -28% 4 36 ND ND ND ND
Fallopian Tube Epithelial 13 -17% 3 36 ND N N N
Peritoneum High Grade Serous 13 -19% 5 30 ND N N N
Uterus Epithelial 13 Non-measurable by RECIST 2 75+ P ND N N
Ovary High Grade Serous 13 -29% 6 24 ND ND ND ND

Abbreviations: ND, not done; N, no; Y, yes; P, present

*

PTEN is tested by immunohistochemistry; absence of PTEN generally indicates an aberration